Skip to main content
Top
Published in: Digestive Diseases and Sciences 8/2020

01-08-2020 | Proton Pump Inhibitors | Original Article

Ninety-Six Hour Wireless Esophageal pH Study in Patients with GERD Shows that Restrictive Diet Reduces Esophageal Acid Exposure

Authors: George Triadafilopoulos, Julia Wilhelmina Korzilius, Thomas Zikos, Irene Sonu, Nielsen Q. Fernandez-Becker, Linda Nguyen, John O. Clarke

Published in: Digestive Diseases and Sciences | Issue 8/2020

Login to get access

Abstract

Background

Prolonged (96 h) pH monitoring may explore the effect of diet on pH and symptoms in patients with GERD.

Aims

To assess the usefulness of a 96 h esophageal pH study in patients with GER symptoms under different diets (pro- and anti-GER).

Methods

Prospective study of 66 patients with GERD undergoing wireless 96 h pH monitoring. Two-day periods, one on liberal (pro-reflux) and another on restricted (anti-reflux) diet assessed esophageal acid exposure and symptoms. The primary end point was normalization of acid exposure time while on restricted diet. Secondary end point was a > 50% reduction in symptoms with restricted diet.

Results

Normal (pH time < 4 of < 6%) was found in 34 patients (51.5%) while on the initial 48 h (liberal) diet [median % time < 4: 3.2 (95% CI, 1.9, 4.0)] and remained normal while on restricted diet [median % time < 4: 2.6 (95% CI, 0.8, 3.4)]. Abnormal acid exposure (% pH time < 4: > 6%) was found in 32 patients (48.5%) while on initial 48 h liberal diet [median % time < 4: 10.5, (95% CI 8.9, 12.6)], and decreased significantly with restricted diet [median % time < 4: 4.5 (95% CI 3.1, 7.3)] (p = 0.001), and normalized with anti-GERD diet in 21 patients (65.6%). Only 11/66 patients were candidates for proton pump inhibitor (PPI) use; 34 had either normal pH studies or normalized them with restricted diet (n = 21). Symptoms did not improve with restricted diet.

Conclusions

The 96-h esophageal pH study tests for GERD under pro- and anti-GER diets and allows minimization of PPI therapy to only 16.6% of patients.
Appendix
Available only for authorised users
Literature
1.
go back to reference Gyawali CP, de Bortoli N, Clarke J, et al. Indications and interpretation of esophageal function testing. Ann N Y Acad Sci. 2018;1434:239–253.CrossRef Gyawali CP, de Bortoli N, Clarke J, et al. Indications and interpretation of esophageal function testing. Ann N Y Acad Sci. 2018;1434:239–253.CrossRef
2.
go back to reference Gyawali CP, Kahrilas PJ, Savarino E, et al. Modern diagnosis of GERD: the Lyon Consensus. Gut. 2018;67:1351–1362.CrossRef Gyawali CP, Kahrilas PJ, Savarino E, et al. Modern diagnosis of GERD: the Lyon Consensus. Gut. 2018;67:1351–1362.CrossRef
3.
go back to reference Hirano I, Richter JE. Practice parameters Committee of the American College of Gastroenterology. ACG practice guidelines: esophageal reflux testing. Am J Gastroenterol. 2007;102:668–685.CrossRef Hirano I, Richter JE. Practice parameters Committee of the American College of Gastroenterology. ACG practice guidelines: esophageal reflux testing. Am J Gastroenterol. 2007;102:668–685.CrossRef
4.
go back to reference Gaddam S, Sathyamurthy A, Kushnir V, et al. Changes in symptom reflux association using dynamic pH thresholds during ambulatory pH monitoring: an observational cross-sectional study. Dis Esophagus. 2016;29:1013–1019.CrossRef Gaddam S, Sathyamurthy A, Kushnir V, et al. Changes in symptom reflux association using dynamic pH thresholds during ambulatory pH monitoring: an observational cross-sectional study. Dis Esophagus. 2016;29:1013–1019.CrossRef
5.
go back to reference Capovilla G, Salvador R, Spadotto L, et al. Long-term wireless pH monitoring of the distal esophagus: prolonging the test beyond 48 hours is unnecessary and may be misleading. Dis Esophagus. 2017;10:1–8.CrossRef Capovilla G, Salvador R, Spadotto L, et al. Long-term wireless pH monitoring of the distal esophagus: prolonging the test beyond 48 hours is unnecessary and may be misleading. Dis Esophagus. 2017;10:1–8.CrossRef
6.
go back to reference Yamasaki T, O’Neil J, Fass R. Update on Functional Heartburn. Gastroenterol Hepatol (N Y).. 2017;13:725–734. Yamasaki T, O’Neil J, Fass R. Update on Functional Heartburn. Gastroenterol Hepatol (N Y).. 2017;13:725–734.
7.
go back to reference Galindo G, Vassalle J, Marcus SN, et al. Multimodality evaluation of patients with gastroesophageal reflux disease symptoms who have failed empiric proton pump inhibitor therapy. Dis Esophagus. 2013;26:443–450.CrossRef Galindo G, Vassalle J, Marcus SN, et al. Multimodality evaluation of patients with gastroesophageal reflux disease symptoms who have failed empiric proton pump inhibitor therapy. Dis Esophagus. 2013;26:443–450.CrossRef
8.
go back to reference Milkes D, Gerson LB, Triadafilopoulos G. Complete elimination of reflux symptoms does not guarantee normalization of intra-esophageal and intra-gastric pH in patients with gastroesophageal reflux disease (GERD). Am J Gastroenterol. 2004;99:991–996.CrossRef Milkes D, Gerson LB, Triadafilopoulos G. Complete elimination of reflux symptoms does not guarantee normalization of intra-esophageal and intra-gastric pH in patients with gastroesophageal reflux disease (GERD). Am J Gastroenterol. 2004;99:991–996.CrossRef
9.
go back to reference Jones R, Junghard O, Dent J, et al. Development of the GerdQ, a tool for the diagnosis and management of gastro-oesophageal reflux disease in primary care. Aliment Pharmacol Ther. 2009;30:1030–1038.CrossRef Jones R, Junghard O, Dent J, et al. Development of the GerdQ, a tool for the diagnosis and management of gastro-oesophageal reflux disease in primary care. Aliment Pharmacol Ther. 2009;30:1030–1038.CrossRef
10.
go back to reference Sami SS, Ragunath K. The Los Angeles classification of gastroesophageal reflux disease. Video J Encycl GI Endosc. 2013;1:103–104.CrossRef Sami SS, Ragunath K. The Los Angeles classification of gastroesophageal reflux disease. Video J Encycl GI Endosc. 2013;1:103–104.CrossRef
11.
go back to reference Austin GL, Thiny MT, Westman EC, et al. A very low-carbohydrate diet improves gastroesophageal reflux and its symptoms. Dig Dis Sci. 2006;51:1307–1312.CrossRef Austin GL, Thiny MT, Westman EC, et al. A very low-carbohydrate diet improves gastroesophageal reflux and its symptoms. Dig Dis Sci. 2006;51:1307–1312.CrossRef
12.
go back to reference Kahrilas PJ, Bredenoord AJ, Fox M, Gyawali CP, et al. International high resolution manometry working group. The Chicago classification of esophageal motility disorders, v.30. Neurogastroenterol Motil. 2015;27:160–174.CrossRef Kahrilas PJ, Bredenoord AJ, Fox M, Gyawali CP, et al. International high resolution manometry working group. The Chicago classification of esophageal motility disorders, v.30. Neurogastroenterol Motil. 2015;27:160–174.CrossRef
13.
go back to reference Dent J, El-Serag HB, Wallander MA. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2005;54:710–717.CrossRef Dent J, El-Serag HB, Wallander MA. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2005;54:710–717.CrossRef
14.
go back to reference Klauser AG, Schindlbeck NE, Muller-Lissner SA. Symptoms in gastro-oesophageal reflux disease. Lancet. 1990;335:205–208.CrossRef Klauser AG, Schindlbeck NE, Muller-Lissner SA. Symptoms in gastro-oesophageal reflux disease. Lancet. 1990;335:205–208.CrossRef
15.
go back to reference Kahrilas PJ, Pandolfino JE. Review article: oesophageal pH monitoring–technologies, interpretation and correlation with clinical outcomes. Aliment Pharmacol Ther. 2005;22:2–9.CrossRef Kahrilas PJ, Pandolfino JE. Review article: oesophageal pH monitoring–technologies, interpretation and correlation with clinical outcomes. Aliment Pharmacol Ther. 2005;22:2–9.CrossRef
16.
go back to reference Penagini R, Sweis R, Mauro A, et al. Inconsistency in the diagnosis of functional heartburn: usefulness of prolonged wireless pH monitoring in patients with proton pump inhibitor refractory gastroesophageal reflux disease. J Neurogastroenterol Motil. 2015;21:265–272.CrossRef Penagini R, Sweis R, Mauro A, et al. Inconsistency in the diagnosis of functional heartburn: usefulness of prolonged wireless pH monitoring in patients with proton pump inhibitor refractory gastroesophageal reflux disease. J Neurogastroenterol Motil. 2015;21:265–272.CrossRef
17.
go back to reference Kaltenbach T, Crockett S, Gerson LB. Are lifestyle measures effective in patients with gastroesophageal reflux disease? An evidence-based approach. Arch Intern Med. 2006;166:965–971.CrossRef Kaltenbach T, Crockett S, Gerson LB. Are lifestyle measures effective in patients with gastroesophageal reflux disease? An evidence-based approach. Arch Intern Med. 2006;166:965–971.CrossRef
18.
go back to reference Gudzune KA, Doshi RS, Mehta AK, et al. Efficacy of commercial weight-loss programs: an updated systematic review. Ann Intern Med. 2015;162:501–512.CrossRef Gudzune KA, Doshi RS, Mehta AK, et al. Efficacy of commercial weight-loss programs: an updated systematic review. Ann Intern Med. 2015;162:501–512.CrossRef
19.
go back to reference Triadafilopoulos G, Zikos T, Regalia K, et al. Use of esophageal pH monitoring to minimize proton-pump inhibitor utilization in patients with gastroesophageal reflux symptoms. Dig Dis Sci. 2018;63:2673–2680.CrossRef Triadafilopoulos G, Zikos T, Regalia K, et al. Use of esophageal pH monitoring to minimize proton-pump inhibitor utilization in patients with gastroesophageal reflux symptoms. Dig Dis Sci. 2018;63:2673–2680.CrossRef
Metadata
Title
Ninety-Six Hour Wireless Esophageal pH Study in Patients with GERD Shows that Restrictive Diet Reduces Esophageal Acid Exposure
Authors
George Triadafilopoulos
Julia Wilhelmina Korzilius
Thomas Zikos
Irene Sonu
Nielsen Q. Fernandez-Becker
Linda Nguyen
John O. Clarke
Publication date
01-08-2020
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 8/2020
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-019-05940-9

Other articles of this Issue 8/2020

Digestive Diseases and Sciences 8/2020 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.